Newswire (Published: Monday, June 26, 2017, Received: Thursday, June 22, 2017, 5:50:45 PM CDT)

Word Count: 397

By a News Reporter-Staff News Editor at Cancer Vaccine Week -- New research on Oncology - Prostate Cancer is the subject of a report. According to news reporting from Philadelphia, Pennsylvania, by NewsRx journalists, research stated, "The genomic landscape of metastatic prostate cancer (mPCa) reveals that up to 90% of patients harbor actionable mutations and 920% have somatic DNA repair gene defects (DRD). This provides the therapeutic rationale of PARP inhibition (PARPi) to achieve 'synthetic lethality' in treating this fatal disease."

The news correspondents obtained a quote from the research from Thomas Jefferson University, "Clinical trials with PARP inhibitors have shown significant response rates up to 88% for PCa patients having DRD like BRCA1/2 or ATM mutations. The FDA has awarded 'breakthrough designation' to develop the PARPi olaparib in treating this subset of metastatic PCa patients. The search for predictive biomarkers has expanded the realm of DNA repair genetic defects and combination genetic platforms are being evaluated as tools to assess potential 'BRCAness' of tumors. Ongoing clinical trials seek to determine the optimal timing and sequence of using these agents in current PCa treatment algorithms. Combination strategies of PARPi with chemo-, radiation, and hormonal therapies, targeted agents, and immunotherapy are promising avenues of current research."

According to the news reporters, the research concluded: "Multi-center international collaborations in well-designed biomarker-driven clinical trials will be key to harness the potential of PARPi in managing a heterogeneous disease like prostate cancer."

For more information on this research see: PARP Inhibitors in Prostate Cancer. Current Treatment Options in Oncology, 2017;18(6):53-68. Current Treatment Options in Oncology can be contacted at: Springer, 233 Spring St, New York, NY 10013, USA. (Springer - www.springer.com; Current Treatment Options in Oncology - www.springerlink.com/content/1527-2729/)

Our news journalists report that additional information may be obtained by contacting W.K. Kelly, Thomas Jefferson University, Sidney Kimmel Canc Center, Philadelphia, PA 19107, United States. Additional authors for this research include M.J. Schiewer, K.E. Knudsen and P.R. Geethakumari (see also Oncology - Prostate Cancer).

Keywords for this news article include: Philadelphia, Pennsylvania, United States, North and Central America, Cancer, Article Review, Diagnostics and Screening, Clinical Trials and Studies, Prostatic Neoplasms, Clinical Research, Prostate Cancer, Oncology, Genetics, Thomas Jefferson University.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC

Companies

Thomas Jefferson University

Industries

Biotechnology
      Biopharmaceuticals
            Immunotherapeutics
Pharmaceuticals
      Biopharmaceuticals
            Immunotherapeutics

Places

Central America
North America
United States
Americas
New York
Pennsylvania
New York City
Philadelphia

Subjects

Science and Technology
      Scientific Research
Health and Wellness
      Medical Conditions and Diseases
            Cancer
                  Prostate Cancer
            Men's Health Issues
                  Prostate Cancer
      Health Sciences
            Genetics
                  Genomics
            Medical Research
      Treatments and Therapies
            Gene and Genetic Therapy